GeneDx To Present New Research At The National Society Of Genetic Counselors Conference, November 11-14; Data Show 62% Of Patients With Pathogenic Or Likely Pathogenic Findings Had Results Associated With Opportunities To Inform Medical Management

Groupon Posts Downbeat Q3 Results, Joins GeneDx Holdings, Qualys And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

Groupon plunged 20% premarket after missing quarterly earnings and sales estimates, while Digital Turbine, Daqo and others also traded lower.

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers Co-Diagnostics (NASDAQ:CODX) stock moved upwards by 22.4% to $0.39 during Tuesday's pre-market session. The company's market cap stands at $2.8 million. As per the press release, Q3 earnings came out

GeneDx Holdings Q3 2026 Earnings Call Transcript

GeneDx Holdings (NASDAQ:WGS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.

GeneDx Holdings Corp. Reports Q3 2026 Financial Results

GeneDx Holdings Corp. announced its third-quarter 2026 financial results, reporting revenue of $123.1 million and adjusted earnings per share of $0.28.

GeneDx Holdings Affirms FY2026 Sales Guidance of $475.000M-$490.000M vs $482.324M Est

8-K filing — GeneDx Holdings Corp. (WGS)

Filed: 2026-11-09 AccNo: 0001628280-26-072172 Size: 6 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits